Sonoma Pharmaceuticals Reports 12% Revenue Growth, Improves Net Loss by 29% in FY2025

Sonoma Pharmaceuticals reported a 12% increase in FY2025 revenue to $14.3 million, a 29% improvement in net loss to $3.5 million, and achieved notable regulatory transitions, including compliance with new EU Medical Device Regulation. The company's revenue in Q4 increased by 9% to $3.8 million, and EBITDA loss improved by 59% in Q4 and 17% for the year.

Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) has reported robust financial results for the fiscal year 2025, highlighting significant growth and regulatory achievements. The company's revenue increased by 12% to $14.3 million, while net loss improved by 29% to $3.5 million [1]. The fourth quarter of 2025 saw revenue grow by 9% to $3.8 million, with EBITDA loss declining by 59% compared to the same period in 2024.

Amy Trombly, CEO of Sonoma Pharmaceuticals, expressed satisfaction with the company's progress: "We are very pleased to report the results of our 2025 fiscal year and fourth fiscal quarter, which show continued revenue growth and consistent progress towards profitability" [1].

Sonoma Pharmaceuticals successfully transitioned all of its commercialized products in Europe to the new European Union (EU) Medical Device Regulation (MDR) ahead of the 2028 deadline. Additionally, five of its products were registered with the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom [1].

The company's strategic expansion of its sales and distribution network, both domestically and internationally, has contributed to its financial performance. In April 2025, Sonoma launched the sale of its hypochlorous acid-based acne products in over 1,200 stores in the United Kingdom through a leading U.K. health and beauty retailer and pharmacy chain. Furthermore, Sonoma expanded its partnership for the sale of Microcyn technology-based products to large retailers in the United States to include additional consumer-focused products [1].

Despite the strong performance, Sonoma Pharmaceuticals remains focused on managing expenses and reducing operational costs. The company reported a decrease in total operating expenses during fiscal year 2025, down by $0.3 million, or 3%, compared to the same period in 2024 [1].

Looking ahead, Sonoma Pharmaceuticals continues to pursue regulatory approvals and market expansions, positioning itself for further growth and profitability. The company's forward-looking statements highlight the potential risks and uncertainties associated with its business, including regulatory challenges and market fluctuations [1].

References:
[1] https://finance.yahoo.com/news/sonoma-pharmaceuticals-reports-fiscal-fourth-201000316.html